# AstraZeneca’s Lynparza recommended for EU marketing authorisation for ovarian cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-lynparza-recommended-for-eu-marketing-authorisation-for-ovarian-cancer/412860061
- Published: 2020-09-21T07:16:35+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD’s _Lynparza_ (olaparib) has been recommended for marketing authorisation
in the European Union for the 1st-line maintenance treatment with bevacizumab of
patients with homologous recombination deficient (HRD)-positive advanced ovarian
cancer.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency based its positive opinion on a biomarker subgroup analysis of thePAOLA-1
Phase III trial, which was published in The New England Journal of Medicine_._

The trial showed that _Lynparza_ in combination with bevacizumab maintenance treatment
reduced the risk of disease progression or death by 67% (based on a hazard ratio
of 0.33; 95% confidence interval 0.25-0.45). The addition of _Lynparza_ improved
progression-free survival (PFS) to a median of 37.2 months versus 17.7 months with
bevacizumab alone in patients with HRD-positive advanced ovarian cancer.

For patients with advanced ovarian cancer, the primary aim of 1st-line treatment
is to delay disease progression for as long as possible with the intent to achieve
long-term remission.^(1-3)

Ovarian cancer is the fifth most common cause of cancer death in Europe and the 
five-year survival rate is approximately 45%, due in part because women are often
diagnosed with advanced disease (Stage III or IV).^(4,5)

> **José Baselga, Executive Vice President, Oncology R&D, said:** “Half of all newly
> diagnosed patients with advanced ovarian cancer have HRD-positive tumours. _Lynparza_
> together with bevacizumab has demonstrated a median progression-free survival 
> benefit of more than three years, offering new hope for women in this setting.
> This recommendation is a vital step toward addressing a significant unmet need
> and could bring a new treatment option that delays relapse in this devastating
> disease.”

> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said:** “HRD is an important biomarker
> of advanced ovarian cancer that can inform how physicians in the EU treat this
> aggressive type of cancer. This recommendation and the results from the PAOLA-
> 1 trial underscore the importance of HRD testing at diagnosis to determine the
> best course of treatment for women with advanced ovarian cancer.”

The CHMP recommendation is for _Lynparza_ in combination with bevacizumab for the
maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-
grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in
response (complete or partial) following completion of 1st-line platinum-based chemotherapy
in combination with bevacizumab and whose cancer is associated with HRD positive
status defined by either a breast cancer susceptibility gene 1/2 (BRCA1/2) mutation
and/or genomic instability.

Further results from the PAOLA-1 trial recently presented during the 2020 European
Society for Medical Oncology virtual congress showed that _Lynparza_ in combination
with bevacizumab maintenance treatment demonstrated a statistically significant 
improvement in the time to second disease progression (PFS2) versus bevacizumab 
alone in patients with HRD-positive advanced ovarian cancer, a key secondary endpoint.
The results showed _Lynparza_ with bevacizumab provided benefit beyond first disease
progression, improving PFS2 to a median of 50.3 months versus 35.3 months with bevacizumab
alone.

_Lynparza_ in combination with bevacizumab is approved in the US and several other
countries as a 1st-line maintenance treatment for patients with HRD-positive advanced
ovarian cancer and is currently under regulatory review in other countries around
the world.

**Ovarian cancer**

In 2018, there were nearly 68,000 new cases of ovarian cancer diagnosed in Europe
and around 45,000 deaths.^(4) Approximately 50% of ovarian cancers are HRD-positive
including BRCA1/2 mutation.^(6,7 )Approximately 22% of ovarian cancers have a BRCA1/
2 mutation.^(6-8)

**Homologous recombination deficiency**

HRD, which defines a subgroup of ovarian cancer, encompasses a wide range of genetic
abnormalities, including BRCA mutations and beyond. As with BRCA gene mutations,
HRD interferes with normal cell DNA repair mechanisms and confers sensitivity to
PARP inhibitors including _Lynparza_.^(9)

**PAOLA-1**

PAOLA-1 is a double-blind Phase III trial testing the efficacy and safety of _Lynparza_ added
to standard-of-care bevacizumab versus bevacizumab alone, as a 1st-line maintenance
treatment for newly diagnosed advanced FIGO Stage III-IV high-grade serous or endometroid
ovarian, fallopian tube, or peritoneal cancer patients who had a complete or partial
response to 1st-line treatment with platinum-based chemotherapy and bevacizumab.
AstraZeneca and MSD announced in August 2019 that the trial met its primary endpoint
of PFS in the overall trial population.

**Lynparza**

_Lynparza_ (olaparib) is a first-in-class PARP inhibitor and the first targeted 
treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency
in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2.
Inhibition of PARP with _Lynparza_ leads to the trapping of PARP bound to DNA single-
strand breaks, stalling of replication forks, their collapse and the generation 
of DNA double-strand breaks and cancer cell death. _Lynparza_ is being tested in
a range of PARP-dependent tumour types with defects and dependencies in the DDR 
pathway.

_Lynparza_ is currently approved in a number of countries, including those in the
EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer.
It is approved in the US, the EU, Japan, China, and several other countries as 1st-
line maintenance treatment of BRCA-mutated advanced ovarian cancer following response
to platinum-based chemotherapy. It is also approved in the US as a 1st-line maintenance
treatment with bevacizumab for patients with HRD-positive advanced ovarian cancer(
BRCAm and/or genomic instability). _Lynparza_ is approved in the US, Japan, and 
a number of other countries for germline BRCA-mutated, HER2-negative, metastatic
breast cancer, previously treated with chemotherapy; in the EU, this includes locally
advanced breast cancer. It is also approved in the US and several other countries
for the treatment of germline BRCAm metastatic pancreatic cancer. _Lynparza_ is 
approved in the US for HRR gene-mutated mCRPC (BRCAm and other HRR gene mutations).
Regulatory reviews are underway in several countries for ovarian, breast, pancreatic
and prostate cancers.

_Lynparza,_ which is being jointly developed and commercialised by AstraZeneca and
MSD, has been used to treat over 30,000 patients worldwide. _Lynparza_ has the broadest
and most advanced clinical trial development programme of any PARP inhibitor, and
AstraZeneca and MSD are working together to understand how it may affect multiple
PARP-dependent tumours as a monotherapy and in combination across multiple cancer
types. _Lynparza_ is the foundation of AstraZeneca’s industry-leading portfolio 
of potential new medicines targeting DDR mechanisms in cancer cells.

Share on:
